.Competing enthusiasms.R.S., M.S., H.G. and A.A.R. are coordinators of the 1M1M project.
H.G. and also A.A.R. are panel of directors participants as well as R.S., M.S.
and also A.A.R. are actually participants of the medical consultatory board of N1C. A.A.R.
reveals work through LUMC, which has licenses on exon-skipping technology, some of which has actually been actually certified to BioMarin and subsequently sublicensed to Sarepta. As co-inventor of a number of these licenses, A.A.R. was allowed to an allotment of nobilities.
A.A.R. additionally makes known functioning as impromptu specialist for PTC Therapeutics, Sarepta Rehabs, Regenxbio, Dyne Therapies, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. In the past 5 years, A.A.R.
also conducted speaking with for Alpha Anomeric. A.A.R. likewise discloses membership of the medical advisory boards of Eisai, Hybridize Therapies, Muteness Therapies, Sarepta Therapies, Sapreme and Mitorx.
Before 5 years, A.A.R. was actually also a clinical advisory board participant for ProQR. Wage for A.A.R.
u00e2 s consulting and also urging activities is actually paid to LUMC. Previously 5 years, LUMC likewise obtained speaker honoraria coming from PTC Therapies, Alnylam Netherlands, Italfarmaco as well as Pfizer and cashing for agreement study from Sapreme, Eisai, Galapagos, Synaffix as well as Alpha Anomeric. Job funding is gotten from Sarepta Rehabs and also Entrada via unconstrained grants.
H.G. possesses absolutely nothing to make known in connection with the subject matters covered within this composition. In the past 5 years, he has actually also received working as a consultant gratuity from UCB.
M.S. obtained working as a consultant gratuity from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly as well as Solaxa previously 5 years, all unrelated to the here and now composition. R.S.
possesses absolutely nothing to reveal in relation to the subjects covered in this manuscript. She has actually received speaker and/or working as a consultant gratuity or funding additions coming from Abbvie, Bial, STADA as well as Everpharma in the past 5 years.